Page 1 | Search Results | Hematology, ASH Education Program

1-20 of 82

Sort by

Sort Order Select

Journal Articles

Targeting CD20: teaching an old dog new tricks

Jeff P. Sharman

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 273–278.

https://doi.org/10.1182/hematology.2019000031

Published: 2019

Journal Articles

Indolent lymphomas: pushing the pace with novel agents

Caron A. Jacobson

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 279–286.

https://doi.org/10.1182/hematology.2019000032

Published: 2019

Journal Articles

Relapsed disease and aspects of undetectable MRD and treatment discontinuation

Barbara Eichhorst, Moritz Fürstenau, Michael Hallek

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 482–489.

https://doi.org/10.1182/hematology.2019000070

Published: 2019

Journal Articles

Molecular profiling and management of mantle cell lymphoma

Jia Ruan

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 30–40.

https://doi.org/10.1182/hematology.2019000011

Published: 2019

Journal Articles

Is there a role for immunosuppression in antiphospholipid syndrome?

Ecem Sevim, Rohan Willis, Doruk Erkan

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 426–432.

https://doi.org/10.1182/hematology.2019000073

Published: 2019

Journal Articles

Where to start? Upfront therapy for follicular lymphoma in 2018

John P. Leonard, Loretta J. Nastoupil, Christopher R. Flowers

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 185–188.

https://doi.org/10.1182/asheducation-2018.1.185

Published: 2018

Journal Articles

Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura

Kathryn Dane, Shruti Chaturvedi

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 539–547.

https://doi.org/10.1182/asheducation-2018.1.539

Published: 2018

Journal Articles

Selecting Frontline Therapy for CLL in 2018

Nitin Jain

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 242–247.

https://doi.org/10.1182/asheducation-2018.1.242

Published: 2018

Journal Articles

Antibody-based therapies in patients with acute lymphoblastic leukemia

Shira Dinner, Michaela Liedtke

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 9–15.

https://doi.org/10.1182/asheducation-2018.1.9

Published: 2018

Journal Articles

Relapsed CLL: sequencing, combinations, and novel agents

Jennifer R. Brown

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 248–255.

https://doi.org/10.1182/asheducation-2018.1.248

Published: 2018

Journal Articles

Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents

Andrés José María Ferreri

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 565–577.

https://doi.org/10.1182/asheducation-2017.1.565

Published: 2017

Journal Articles

The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment

Gianluca Gaidano, Davide Rossi

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 329–337.

https://doi.org/10.1182/asheducation-2017.1.329

Published: 2017

Journal Articles

How should we sequence and combine novel therapies in CLL?

Matthew S. Davids

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 346–353.

https://doi.org/10.1182/asheducation-2017.1.346

Published: 2017

Journal Articles

Secondary CNS relapse in diffuse large B-cell lymphoma: defining high-risk patients and optimization of prophylaxis strategies

Kerry J. Savage

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 578–586.

https://doi.org/10.1182/asheducation-2017.1.578

Published: 2017

Journal Articles

Safety profiles of novel agent therapies in CLL

Inhye E. Ahn, Matthew S. Davids

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 354–357.

https://doi.org/10.1182/asheducation-2017.1.354

Published: 2017

Journal Articles

Incorporation of nonchemotherapeutic agents in pediatric acute lymphoblastic leukemia

Lewis B. Silverman

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 259–264.

https://doi.org/10.1182/asheducation-2017.1.259

Published: 2017

Journal Articles

Follicular lymphoma: are we ready for a risk-adapted approach?

Brad S. Kahl

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 358–364.

https://doi.org/10.1182/asheducation-2017.1.358

Published: 2017

Journal Articles

Optimizing therapy for mantle cell lymphoma

Peter Martin

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 304–309.

https://doi.org/10.1182/asheducation-2017.1.304

Published: 2017

Journal Articles

Sequencing of chronic lymphocytic leukemia therapies

Jacqueline C. Barrientos

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 128–136.

https://doi.org/10.1182/asheducation-2016.1.128

Published: 2016

Journal Articles

Novel agents in chronic lymphocytic leukemia

Nicole Lamanna, Susan O’Brien

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 137–145.

https://doi.org/10.1182/asheducation-2016.1.137

Published: 2016

NARROW

Targeting CD20: teaching an old dog new tricks

Indolent lymphomas: pushing the pace with novel agents

Relapsed disease and aspects of undetectable MRD and treatment discontinuation

Molecular profiling and management of mantle cell lymphoma

Is there a role for immunosuppression in antiphospholipid syndrome?

Where to start? Upfront therapy for follicular lymphoma in 2018

Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura

Selecting Frontline Therapy for CLL in 2018

Antibody-based therapies in patients with acute lymphoblastic leukemia

Relapsed CLL: sequencing, combinations, and novel agents

Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents

The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment

How should we sequence and combine novel therapies in CLL?

Secondary CNS relapse in diffuse large B-cell lymphoma: defining high-risk patients and optimization of prophylaxis strategies

Safety profiles of novel agent therapies in CLL

Incorporation of nonchemotherapeutic agents in pediatric acute lymphoblastic leukemia

Follicular lymphoma: are we ready for a risk-adapted approach?

Optimizing therapy for mantle cell lymphoma

Sequencing of chronic lymphocytic leukemia therapies

Novel agents in chronic lymphocytic leukemia

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only